HBM Healthcare Investments : Bioverativ acquires HBM-portfolio company True North Therapeutics for up to USD 825 million plus assumed cash

Media Release

Zug, 23 May 2017

Bioverativ Inc. (Nasdaq: BIVV) and True North Therapeutics, a privately held portfolio company of HBM Healthcare Investments, today announced the signing of a definitive agreement under which Bioverativ acquires all outstanding shares of True North for a total upfront payment of USD 400 million plus assumed cash. True North investors are also eligible to receive additional payments of up to USD 425 million contingent on the achievement of future development, regulatory and sales milestones.

HBM Healthcare Investments participated with USD 10 million in the HBM-led Series D financing of True North Therapeutics in October 2016 and holds slightly more than 3 percent of the company.

True North develops its lead complement inhibitor, TNT009, for Cold Agglutinin Disease (CAD), as well as other rare diseases affected by the C1s serine protease in the complement system. Cold agglutinins are antibodies of the blood, normally made by the immune system in response to infection. They cause red blood cells to clump together (agglutinate) at low temperatures. As a result, the red blood cells can be destroyed, which can lead to anemia, fatigue and potentially fatal thromboses. There are currently no approved pharmaceutical products in the U.S. or Europe for the treatment of this rare autoimmune disease.

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

True North Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class product candidates for Complement-mediated

diseases in hematology, transplantation, and dermatology. True North Therapeutics is located in South San Francisco, California. For more information, please visit www.truenorthrx.com.

Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Bioverativ was launched in 2017 following separation from Biogen Inc. For more information, visit www.bioverativ.com.

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.